Team PHenomenal Hope’s research fund, the PHenomenal Impact Fund for Global PH Research, will help finance pulmonary hypertension…
Yedida Y Bogachkov PhD
Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Yedida Y Bogachkov PhD
A new study highlights the predictive utility of hypochromic erythrocytes — red blood cells that have decreased levels of hemoglobin…
Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest…
Circulating endostatin, a protein that inhibits new blood vessel formation, appears to correlate well with mortality and disease severity in…
Children undergoing high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) to treat their cancer should be screened for pulmonary…
Opsynvi, a fixed-dose oral combination of macitentan and tadalafil, was approved by Health Canada for the long-term treatment of pulmonary arterial…